In an ambitious move to counter declining fertility rates, Malaysia has inaugurated its first National Subfertility Centre. This strategic initiative targets subfertility, a condition that lowers normal fertility levels and contributes to the nation's dwindling birth rates. The Centre aims to provide comprehensive assistance to couples struggling to conceive, thereby boosting population growth and ensuring Malaysia's demographic stability.
Addressing Subfertility: A National Concern
Subfertility has emerged as a significant factor in Malaysia's decreasing birth rates. To reverse this trend, the National Subfertility Centre will offer specialized treatments and support, marking a significant stride in tackling demographic challenges. By doing so, it also contributes to sustaining the nation's socio-economic development. This initiative underlines the government's commitment to addressing fertility issues, thereby ensuring a robust future population.
FemaSeed: A Pioneering Approach to Infertility
Biomedical company Femasys Inc. has recently concluded enrollment in the LOCAL FemaSeed pivotal clinical trial. This trial is designed to evaluate women undergoing FemaSeed cycles due to male factor infertility. FemaSeed employs an intratubal insemination approach that delivers sperm directly to the fallopian tube - the site of conception. This method is less invasive and more affordable than other reproductive procedures like in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The trial aims to determine the effectiveness pregnancy rate and safety over a seven-week period post FemaSeed procedure.
Global Market for Infertility Treatments
The global market for infertility treatments is projected to grow at an 8.2% CAGR from 2023 to 2030. Valued at USD 1.75 billion in 2023, it is expected to exceed USD 3.04 billion by 2030. Factors such as the falling fertility rate, increase in fertility clinics worldwide, technological advancements, and the surge in public-private investments have influenced this market. However, the high cost of infertility treatments and the lack of specialists are potential constraints to market expansion. Furthermore, policy decisions and the need for infertility treatments to be covered by insurance plans also impact the market's success.